Oncoinvent ASA Approves Reverse Share Split

(AWP Alliance News) - Oncoinvent ASA has approved a reverse share split following an extraordinary general meeting held electronically on January 8, 2026. The decision was recorded in the official meeting minutes available on the company's website. https://news.cision.com/oncoinvent-asa/r/oncoinvent-asa--minutes-from-extraordinary-general-meeting,c4289947 Disclaimer: This news brief was created using generative artificial intelligence. Oncoinvent ASA published the original co…

Oncoinvent ASA: Minutes from Extraordinary General Meeting

Oslo, Norway, 8 January 2026: An extraordinary general meeting of the Companywas held today, 8 January 2026, by electronic means through Lumi AGM. Thegeneral meeting, inter alia, resolved i) audited interim balance sheet, ii) areverse share split, iii) a capital reduction, and iv) proxy to the Board ofDirectors.The complete minutes of the extraordinary general meeting are attached to thisrelease and are also available on the Company's website,https://www.oncoinvent.com/.Pleas…

Oncoinvent ASA: Minutes from Extraordinary General Meeting

Oncoinvent ASA Grants 25.8 Million New Share Options to Employees and Insiders

(AWP Alliance News) - Oncoinvent ASA has announced the grant of a new share option program following its merger with BerGenBio. The Board of Directors has allocated a total of 6,355,096 replacement share options to employees and board members, adjusting the terms to reflect the merger exchange ratio and ensure a value-neutral transition. In addition, 25,770,000 new share options have been granted, representing 5.4% of fully diluted shares, at a strike price of NOK 0.50 per op…

Oncoinvent ASA: Grant of share options - mandatory notification of trade

Oslo, Norway, 22 December 2025: Oncoinvent ASA ("Oncoinvent" or the "Company")(OSE: ONCOIN), a clinical stage, radiopharmaceutical company developinginnovative treatments for solid cancers, today announce that the Board ofDirectors has granted options to employees.As previously communicated and with the objective of aligning share optionparticipants' interests with those of the shareholders of the Combined Company,the Board of Directors has established a replacement share opt…

Oncoinvent ASA: Grant of share options - mandatory notification of trade

Oncoinvent ASA Announces Reverse Share Split

(AWP Alliance News) - Oncoinvent ASA has called an extraordinary general meeting to be held on January 8, 2026, where one of the agenda items is the approval of a reverse share split. https://www.publicnow.com/view/CDE4C6D630D08D9BAD6AA1C8BC8385A1EFFE28F9/117424 Disclaimer: This news brief was created using generative artificial intelligence. Oncoinvent ASA published the original content used to generate this news brief on December 18, 2025, and is solely responsible for the …

Oncoinvent ASA: Notice of Extraordinary General Meeting

18 December 2025: Oncoinvent ASA (the "Company") hereby calls for anextraordinary general meeting to be held on Thursday 8 January at 11:30 hours(CET) to, inter alia, resolve approval of a i) audited interim balance sheet,ii) a reverse share split, iii) a capital reduction, and iv) proxy to the Boardof Directors. The Company hereby calls for an extraordinary general meeting tobe held on Thursday 8 January 2026 at 11:30 hours (CET).The extraordinary general meeting will be hel…

Oncoinvent ASA: Notice of Extraordinary General Meeting

Oncoinvent ASA: New share capital registered

10 December 2025: Reference is made to the stock exchange announcementspublished by Oncoinvent ASA (the "Company") on 30 June 2025 and 4 August 2025,and subsequent announcements, regarding the contemplated fully underwrittenrights issue of 260,000,000 new shares in the Company (the "Offer Shares")raising gross proceeds of NOK 130 million (the "Rights Issue"). Further,reference is made to the stock exchange announcement published by the Company on5 December 2025 regarding the …

Oncoinvent ASA: New share capital registered

Flaggemelding - Hadean Ventures AS / HVentures AB / Hadean Growth Fund I AS1 - Oncoinvent AS (ONCIN)

1. Navn på meldepliktig:Hadean Ventures AS, HVentures AB og Hadean Growth Fund I AS1 (Aksjene eies avfond som forvaltes av Hadean Ventures AS og HVentures AB

Oncoinvent ASA Announces Allocation of UWC Shares to Primary Insider

(AWP Alliance News) - Oncoinvent ASA has announced the subscription and allocation of UWC shares by a primary insider or close associate, as part of a notification of trade. This reflects the exercise or issuance of share rights within the company. https://www.publicnow.com/view/85F0DA6E05995B03BBC1B5430BB044DA9D32BF95/117424 Disclaimer: This news brief was created using generative artificial intelligence. Oncoinvent ASA published the original content used to generate this ne…

Oncoinvent Publishes Positive Phase 1 Results for Radspherin in Ovarian Cancer

(AWP Alliance News) - Oncoinvent ASA has announced the publication of 12-month results from its Phase 1 study of Radspherin(R), an alpha-emitting radiopharmaceutical therapy, in patients with platinum-sensitive recurrent ovarian cancer and peritoneal carcinomatosis. The study results have been published in the peer-reviewed journal Gynecologic Oncology. The Phase 1 trial evaluated the safety and tolerability of 224Ra-labeled microparticles administered intraperitoneally follo…

ONCIN: Oncoinvent Announces Publication of Phase 1 Study Results for Radspherin® in Ovarian Cancer in Gynecologic Oncology

Oslo, Norway, 8 December 2025 - Oncoinvent, a clinical stage,radiopharmaceutical company developing innovative treatments for solid cancers,today announced the publication of 12-month data from its Phase 1 study ofpatients with platinum-sensitive recurrent ovarian cancer and peritonealcarcinomatosis. The results from the first patients have been published in therespected peer-reviewed journal Gynecologic Oncology, under the title: "Firstexperience with intraperitoneal 224Ra-l…

Oncoinvent ASA: Oncoinvent Announces Publication of Phase 1 Study Results for Radspherin® in Ovarian Cancer in Gynecologic Oncology

Oncoinvent ASA: Notification of trade - primary insider/close associate

8 December 2025: Reference is made to the stock exchange announcements publishedby Oncoinvent ASA (the "Company") on 30 June 2025 and 4 August 2025, andsubsequent announcements, regarding the fully underwritten rights issue of260,000,000 new shares in the Company (the "Offer Shares") raising grossproceeds of NOK 130 million (the "Rights Issue"). Further, reference is made tothe stock exchange announcement published by the Company on 5 December 2025regarding the resolution by …

Oncoinvent ASA: Notification of trade - primary insider/close associate

ONCIN: NOTIFICATION OF MAJOR HOLDINGS

Please see attachment on www.newsweb.no

Oncoinvent ASA: Resolution to increase the share capital in connection with settlement of underwriting fee

5 December 2025: Reference is made to the stock exchange announcements publishedby Oncoinvent ASA (the "Company") on 30 June 2025 and 4 August 2025, andsubsequent announcements, regarding the contemplated fully underwritten rightsissue of 260,000,000 new shares in the Company (the "Offer Shares") raisinggross proceeds of NOK 130 million (the "Rights Issue").In connection with the Rights Issue, a total of 31,199,997 new shares, each at asubscription price of NOK 0.50 (the "Und…

Oncoinvent · 2024 financial report

Oncoinvent · 2024-Q3 financial report

Oncoinvent · 2024-Q2 financial report

Oncoinvent · 2024-Q1 financial report